Modena CEO warns that a fourth dose of the vaccine may be needed this fall

According to CNBC Eastern Time reported on the 6th, Moderna CEO Stephane Bancel warned that the effectiveness of the strengthening needle may decline over time, and people may need to start injecting the fourth dose of the vaccine this fall to enhance protection.

Bancel said those who had already been vaccinated against the company last fall were likely to receive enough protection to survive the winter. However, he said at a meeting of healthcare CEOs at Goldman Sachs that the efficacy of a third dose of the vaccine could decline over the course of a few months, similar to the first two doses.

"When we get the data in the coming weeks, I'm going to be surprised if it [the potency of the reinforcing needle] remains good over time because I don't expect it to hold up very well."

Preliminary data released by Modena last month showed that the company's currently approved 50-microgram booster needle could increase the number of antibodies blocking Theomilon infection by 37 times. The 100-microgram booster needle increased these antibodies by a factor of 83.

Omikeron severely weakened the effectiveness of the two doses of the vaccine. Data released by the United Kingdom found that two doses of the Modena and Pfizer vaccines were only about 10% effective in preventing symptomatic infections caused by Omiljung after 20 weeks of full vaccination.

U.K. Health Security Authority (U.K. The same study, published by the Health Security Agency, found that up to 75 percent effective in preventing symptomatic infections after two weeks of injections.

However, according to the study, the effect of the strengthening needle began to decline after about four weeks. At weeks 5 to 9, the effectiveness of the booster needle in preventing infection is 55% to 70%, and the effectiveness after 10 weeks of vaccination is 40% to 50%.

Pfizer CEO Albert Bourla also said in an interview with CNBC last month that people may need a fourth dose of the vaccine, which could be earlier than expected given the toxicity of Omilon.

Bancel estimates that random mutations could once again alter the course of the pandemic.

"It's completely impossible to predict whether a new mutation will emerge over the course of a day, week or three that will make the condition worse." This is an issue that we must be careful about. ”

According to the real-time statistics system of global new crown pneumonia data released by Johns Hopkins University in the United States, as of 1 p.m. Eastern Time on January 7, 2022, a total of 58.487 million confirmed cases of new crown pneumonia and more than 830,000 deaths have been reported in the United States.

Previously, the data showed that the number of new confirmed cases of new coronavirus in the United States exceeded 1 million on the 3rd of this month, once again refreshing the record for the highest number of new cases in a single day since the outbreak of the epidemic.